marketcaparena
Search

    CTSO

    Cytosorbents Corp

    Company overview

    Market capitalization
    —
    Employees
    129
    Latest publication
    2026-09-29
    About Cytosorbents Corp

    Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue9,633,000USD8,864,000USD9,234USD9,485,000USD9,617,000USD8,727,238USD9,786,000,000USD9,390,388USD
    Cost Of Revenue2,584,000USD2,734,000USD2,430USD2,819,000USD2,803,000USD2,519,641USD2,656,446,000,000USD4,108,773USD
    Gross Profit7,049,000USD6,130,000USD6,804USD6,666,000USD6,814,000USD6,207,597USD6,493,970,000,000USD5,281,615USD
    Research Development1,453,000USD1,025,000USD1,243USD———1,324,353,000,000USD1,851,230USD
    Selling General Administrative7,964,000USD8,149,000USD9,612USD8,610,000USD9,167,000USD8,431,880USD8,898,722,000,000USD7,002,718USD
    Total Operating Expenses9,687,000USD9,174,000USD11,365USD9,528,000USD10,429,000USD10,094,805USD10,223,076,000,000USD9,677,862USD
    Operating Income-2,638,000USD-3,044,000USD—-2,862,000USD-3,615,000USD-3,887,208USD—-4,396,247USD
    Total Other Income Expense Net-1,779,000USD-2,085,000USD—-709,000USD5,562,000USD2,408,850USD—2,062,156USD
    Net Income-4,417,000USD-5,129,000USD-5,497USD-3,170,000USD1,947,000USD-1,478,358USD-7,567,613,000,000USD-2,334,091USD
    Income Before Tax—-5,129,000USD—-3,571,000USD—-1,478,358USD—-2,334,091USD
    Income Tax Expense—0USD—-401,000USD—0USD1,691,000USD0USD
    Net Income Applicable To Common Shares—-5,129,000USD—-3,170,000USD1,947,000USD——-2,334,091USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosurePreliminaryDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosurePreliminaryDisclosureDeterministicFinal

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20122012-12-31 · USDFY 20102010-12-31 · USDFY 20092009-12-31 · USDFY 20082008-12-31 · USDFY 20052005-12-31 · USDFY 20042004-12-31 · USD
    Total Revenue37,063,000USD35,594,520USD151,574USD———10,000USD10,000USD
    Cost Of Revenue10,572,000USD10,468,529USD319,298USD———10,000USD10,000USD
    Gross Profit26,491,000USD25,125,991USD-167,724USD—————
    Selling General Administrative35,645,000USD34,995,749USD1,981,983USD1,066,649USD757,450USD909,372USD70,000USD70,000USD
    Total Operating Expenses41,240,000USD41,911,930USD3,323,110USD2,824,019USD3,027,362USD3,244,212USD80,000USD80,000USD
    Operating Income-14,749,000USD-16,785,939USD-3,490,834USD-2,824,019USD-2,429,784USD-3,244,212USD-80,000USD-80,000USD
    Total Other Income Expense Net6,150,000USD-5,623,843USD-564,428USD5,732,884USD12,142,016USD-22,207USD——
    Income Before Tax-8,599,000USD-22,409,782USD-4,055,262USD2,908,865USD-3,035,504USD-3,266,419USD-80,000USD-80,000USD
    Income Tax Expense-401,000USD-1,690,825USD-391,756USD5,817,730USD-298,789USD-248,529USD——
    Net Income-8,198,000USD-20,718,957USD-3,663,506USD-2,908,865USD-2,736,715USD-3,017,890USD-80,000USD-80,000USD
    Net Income Applicable To Common Shares-8,198,000USD-20,718,957USD——————
    Research Development——2,532,489USD1,757,370USD1,961,960USD1,983,483USD——
    Unclassified Operating Expenses——-1,191,362USD—————
    Interest Expense——564,428USD84,846USD8,142USD22,207USD0USD0USD
    Ebit——-3,490,834USD-2,823,104USD-3,027,362USD-3,244,212USD-80,000USD-80,000USD
    Ebitda——-3,436,228USD-2,805,300USD-2,975,667USD-3,140,511USD-70,000USD-70,000USD
    Depreciation And Amortization——54,606USD17,804USD51,695USD103,701USD10,000USD10,000USD
    Selling And Marketing Expenses————307,952USD351,357USD——
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets37,960,000USD40,562,000USD44,182,000USD45,750,000USD47,990,000USD50,781,684USD47,371,500USD47,804,011USD
    Cash And Equivalents4,413,000USD4,813,000USD6,249,000USD7,536,000USD10,204,000USD11,587,275USD3,279,926USD5,685,328USD
    Total Current Assets15,737,000USD17,757,000USD20,634,000USD21,313,000USD22,987,000USD25,412,904USD21,603,242USD16,597,368USD
    Other Current Assets852,000USD1,311,000USD1,554,000USD2,348,000USD1,330,000USD3,136,706USD3,270,812USD1,031,694USD
    Other Non Current Assets53,000USD52,000USD53,000USD3,647,000USD3,792,000USD3,755,029USD3,770,681USD3,801,223USD
    Total Liabilities38,711,000USD38,368,000USD38,279,000USD36,730,000USD36,404,000USD36,238,900USD36,264,564USD34,804,921USD
    Total Current Liabilities24,023,000USD16,303,000USD9,709,000USD10,112,000USD9,842,000USD9,736,066USD9,824,243USD8,430,191USD
    Total Stockholder Equity-751,000USD2,194,000USD5,903,000USD9,020,000USD11,586,000USD14,542,784USD11,106,936USD12,999,090USD
    Total Equity Including Noncontrolling Interest-751,000USD2,194,000USD5,903,000USD9,020,000USD11,586,000USD14,542,784USD11,106,936USD12,999,090USD
    Short Long Term Debt14,149,000USD13,292,000USD——————
    Long Term Debt3,092,000USD10,313,000USD16,667,000USD14,567,000USD14,377,000USD14,186,715USD13,996,350USD13,805,985USD
    Net Receivables6,786,000USD7,152,000USD7,550,000USD7,427,000USD7,743,000USD7,670,399USD7,319,597USD6,632,590USD
    Inventory3,686,000USD4,481,000USD5,281,000USD4,002,000USD3,710,000USD3,018,524USD2,732,907USD3,247,756USD
    Property Plant Equipment Net17,784,000USD18,279,000USD18,747,000USD19,268,000USD19,689,000USD20,091,293USD20,513,619USD20,921,462USD
    Accounts Payable2,002,000USD3,132,000USD2,869,000USD3,035,000USD3,394,000USD3,325,386USD3,339,885USD2,338,143USD
    Short Term Debt589,000USD565,000USD541,000USD518,000USD495,000USD473,889USD452,688USD431,997USD
    Common Stock63,000USD63,000USD63,000USD63,000USD63,000USD62,529USD54,830USD54,498USD
    Retained Earnings-321,754,000USD-317,336,000USD-312,207,000USD-306,710,000USD-303,540,000USD-305,486,976USD-304,008,618USD-295,340,370USD
    Accumulated Other Comprehensive Income-996,000USD-2,101,000USD-2,977,000USD-3,844,000USD-3,960,000USD1,515,659USD4,252,013USD-156,925USD
    Deferred Revenue—34,000USD182,000USD403,000USD361,000USD546,028USD419,331USD—
    Other Current Liabilities————965,000USD796,925USD865,510USD—
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinal

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets44,182,000USD47,371,500USD53,260,634USD63,231,530USD89,519,282USD89,950,471USD27,383,000USD32,747,326USD
    Cash And Equivalents6,249,000USD3,279,926USD——————
    Total Current Assets20,634,000USD21,603,242USD25,702,823USD33,759,691USD64,298,890USD82,453,135USD20,902,000USD28,264,087USD
    Other Current Assets1,554,000USD3,270,812USD1,834,485USD2,488,597USD2,871,655USD3,198,460USD2,087,913USD1,118,998USD
    Other Non Current Assets53,000USD3,770,681USD——————
    Total Liabilities38,279,000USD36,264,564USD——————
    Total Current Liabilities9,709,000USD9,824,243USD14,545,955USD9,714,552USD13,690,142USD10,153,254USD9,936,000USD6,538,199USD
    Total Stockholder Equity5,903,000USD11,106,936USD23,275,163USD35,374,973USD62,578,197USD79,215,579USD3,418,000USD16,934,600USD
    Total Equity Including Noncontrolling Interest5,903,000USD11,106,936USD——————
    Long Term Debt16,667,000USD13,996,350USD2,542,857USD5,000,000USD——13,385,522USD9,274,527USD
    Deferred Revenue182,000USD419,331USD——————
    Net Receivables7,550,000USD7,319,597USD6,057,072USD5,664,941USD4,523,430USD5,159,275USD4,467,087USD3,943,119USD
    Inventory5,281,000USD2,732,907USD3,680,129USD3,461,586USD4,766,098USD2,673,799USD2,114,000USD833,133USD
    Property Plant Equipment Net18,747,000USD20,513,619USD22,115,250USD23,346,933USD18,574,358USD3,149,050USD2,996,000USD1,729,860USD
    Accounts Payable2,869,000USD3,339,885USD3,802,170USD1,655,173USD2,805,235USD2,466,724USD2,039,222USD1,965,595USD
    Short Term Debt541,000USD452,688USD2,873,636USD108,939USD570,566USD447,485USD2,522,832USD666,667USD
    Common Stock63,000USD54,830USD54,240USD43,635USD43,478USD43,222USD32,616USD31,774USD
    Retained Earnings-312,207,000USD-304,008,618USD-282,505,272USD-253,997,878USD-221,185,295USD-196,626,647USD-188,789,459USD-169,523,815USD
    Accumulated Other Comprehensive Income-2,977,000USD4,252,013USD529,321USD2,329,195USD525,585USD-1,734,078USD525,978USD288,175USD
    Other Current Liabilities—865,510USD——————
    Intangible Assets——3,906,552USD4,390,533USD4,701,984USD4,222,394USD3,361,412USD2,625,265USD
    Total Liab——29,985,471USD27,856,557USD26,941,085USD10,734,892USD23,965,000USD15,812,726USD
    Other Current Liab——6,432,905USD6,411,797USD7,581,170USD6,204,842USD4,813,474USD3,905,937USD
    Capital Stock——54,240USD43,635USD43,478USD43,222USD32,616USD31,774USD
    Cash——14,131,137USD22,144,567USD52,137,707USD71,421,601USD12,233,000USD22,368,837USD
    Cash And Short Term Investments——14,131,137USD22,144,567USD52,137,707USD71,421,601USD12,233,000USD22,368,837USD
    Current Deferred Revenue——1,380,821USD1,516,772USD1,947,353USD1,034,203USD157,656USD—
    Net Debt——4,182,015USD-3,893,623USD-38,316,198USD-70,392,478USD4,318,033USD-12,427,643USD
    Short Long Term Debt——2,500,000USD———1,666,666USD666,667USD
    Short Long Term Debt Total——18,313,152USD18,250,944USD13,821,509USD1,029,123USD16,551,033USD9,941,197USD
    Property Plant Equipment Gross——25,151,280USD23,347,000USD18,574,000USD3,149,050USD2,996,087USD1,729,860USD
    Common Stock Shares Outstanding——44,656,391shares43,573,215shares43,359,186shares38,818,990shares32,255,253shares30,719,176shares
    Non Current Assets Total——27,557,811USD29,471,839USD25,220,392USD7,497,336USD6,481,000USD4,483,239USD
    Non Current Liabilities Total——15,439,516USD18,142,004USD13,250,943USD581,638USD14,029,000USD9,274,527USD
    Non Currrent Assets Other——-3,653,620USD1,734,467USD1,944,016USD4,348,000USD3,485,000USD4,483,239USD
    Net Working Capital——11,156,868USD24,045,139USD50,608,748USD72,299,881USD10,965,262USD21,725,888USD
    Unclassified Non Current Assets——1,536,009USD-1,734,467USD-6,645,966USD-13,947,803USD-6,969,788USD-7,236,618USD
    Unclassified Current Liabilities——-2,443,577USD———-1,263,850USD—
    Unclassified Non Current Liabilities——12,896,659USD13,142,004USD13,250,943USD———
    Unclassified Equity——305,142,634USD286,956,386USD283,150,951USD277,489,860USD191,616,249USD186,106,692USD
    Other Assets———1,734,373USD6,646,000USD5,377,409USD123,482USD128,114USD
    Net Tangible Assets———35,374,973USD62,578,000USD79,215,579USD56,630USD14,309,335USD
    Good Will—————4,222,394USD3,361,412USD2,625,265USD
    Long Term Investments—————125,892USD123,482USD128,114USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Stock Based Compensation544,000USD1,458,574USD488,000USD572,574USD818,426USD1,511,131USD486,515USD837,584USD
    Change To Account Receivables310,000USD-137,000USD—336,889USD-79,889USD-1,091,909USD1,323,903USD-1,104,083USD
    Change To Inventory723,000USD-1,293,000USD—-726,198USD-198,802USD71,462USD1,155,000USD-600,439USD
    Change To Liabilities92,000USD———-367,282USD———
    Change In Working Capital1,255,000USD-1,165,000USD—1,257,042USD-388,042USD-1,518,758USD1,275,595USD-2,765,765USD
    Operating Cash Flow-1,162,000USD———-3,464,955USD———
    Capital Expenditures-11,000USD-62,883USD-56,000USD-36,875USD-2,121USD-124,193USD-298,354USD-119,865USD
    Unclassified Investing Cash Flow-35,000USD———-45,121USD———
    Investing Cash Flow-46,000USD—-124,000USD—-47,242USD———
    Effect Of Forex Changes On Cash-228,000USD———25,912USD———
    Change In Cash-1,436,000USD-1,287,000USD-706,000USD-1,383,275USD3,345,849USD-2,405,402USD-2,773,380USD-149,672USD
    End Cash Flow6,335,000USD—9,058,000USD—13,100,000USD———
    Net Income—-5,496,642USD-3,170,000USD1,947,000USD—-7,883,859USD-2,334,091USD-4,143,146USD
    Depreciation—-291,000USD364,000USD440,252USD368,503USD425,631USD428,770USD446,514USD
    Other Non Cash Items—669,068USD—-5,154,339USD—5,123,688USD-2,318,019USD830,160USD
    Total Cash From Operating Activities—-4,825,000USD—-1,510,045USD—-2,342,167USD-2,461,230USD-4,794,653USD
    Free Cash Flow—-4,887,883USD—-1,546,920USD—-2,466,360USD-2,759,584USD-4,914,518USD
    Total Cashflows From Investing Activities—-291,000USD—-131,758USD—-124,193USD-298,354USD-118,982USD
    Net Borrowings—2,478,000USD—0USD—0USD0USD—
    Total Cash From Financing Activities—2,478,000USD—-1,134USD—166,860USD-99,031USD9,834,637USD
    Issuance Of Capital Stock—0USD—-306USD—166,860USD-41,456USD12USD
    Begin Period Cash Flow—9,058,000USD—11,587,275USD—12,169,286USD14,942,666USD8,608,380USD
    End Period Cash Flow—7,771,000USD—10,204,000USD—9,763,884USD12,169,286USD8,458,708USD
    Other Cashflows From Investing Activities—-323,000USD———-55,008USD-146,617USD-101,635USD
    Other Cashflows From Financing Activities—5,391,172USD———9,359,625USD-57,575USD-150,000USD
    Unclassified Financing Cash Flow—-5,391,172USD———-9,359,625USD—9,984,625USD
    Financing Cash Flow——6,831,000USD—6,832,134USD———
    Investments———-131,758USD—-124,193USD-298,354USD-119,865USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyDisclosurePreliminaryLegacy providerLegacyDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Depreciation1,234,000USD1,570,104USD2,026,792USD1,131,629USD1,129,613USD660,788USD581,532USD390,551USD
    Stock Based Compensation2,765,000USD3,759,534USD3,700,704USD3,800,091USD6,204,136USD4,707,620USD2,839,767USD5,385,160USD
    Change To Account Receivables423,000USD-1,720,419USD-245,616USD-1,288,422USD420,578USD-326,860USD-642,171USD-1,847,848USD
    Change To Inventory-2,540,000USD500,466USD-121,039USD945,352USD-2,350,547USD-461,512USD-1,284,848USD-56,751USD
    Change To Liabilities-706,000USD-1,807,575USD—-3,248,978USD2,426,810USD1,107,352USD1,424,440USD1,704,845USD
    Change In Working Capital-1,030,000USD-4,378,283USD2,361,042USD-3,561,557USD641,899USD-757,869USD-1,452,437USD-937,771USD
    Operating Cash Flow-12,377,000USD-14,427,809USD——————
    Capital Expenditures-164,000USD-284,343USD-936,236USD-6,455,576USD-4,281,261USD-1,676,218USD-1,520,117USD-1,520,264USD
    Unclassified Investing Cash Flow-251,000USD-385,087USD1,404,515USD6,823,787USD4,921,274USD2,644,041USD2,342,069USD2,368,558USD
    Investing Cash Flow-415,000USD-669,430USD——————
    Net Debt Issuance2,478,000USD10,000,000USD——————
    Unclassified Financing Cash Flow6,831,000USD-669,296USD—5,040,358USD-5,000,000USD78,704,686USD-1,834,585USD10,787,197USD
    Financing Cash Flow9,309,000USD9,330,704USD——————
    Effect Of Forex Changes On Cash1,490,000USD-84,676USD——————
    Change In Cash-1,993,000USD-5,851,211USD-8,216,931USD-29,993,140USD-17,596,435USD59,189,183USD-10,136,419USD5,046,975USD
    End Cash Flow7,771,000USD9,763,884USD——————
    Net Income——-28,507,394USD-32,812,583USD-24,558,648USD-7,837,188USD-19,265,644USD-17,211,179USD
    Other Non Cash Items——-1,236,280USD3,208,138USD2,577,401USD322,812USD115,206USD734,041USD
    Total Cash From Operating Activities——-21,655,136USD-28,234,282USD-14,005,599USD-5,613,286USD-16,758,782USD-10,839,684USD
    Free Cash Flow——-22,591,372USD-34,689,858USD-18,286,860USD-7,289,504USD-18,278,899USD-12,359,948USD
    Investments——-1,006,394USD-6,455,576USD-4,281,261USD-1,676,218USD-1,520,117USD-1,520,264USD
    Total Cashflows From Investing Activities——-936,236USD-6,455,576USD-4,281,261USD-1,676,218USD-1,520,117USD-1,520,264USD
    Net Borrowings——0USD5,000,000USD5,000,000USD-15,000,000USD5,000,000USD-147,988USD
    Total Cash From Financing Activities——14,474,210USD4,959,642USD715,199USD66,348,330USD8,177,679USD17,465,853USD
    Issuance Of Capital Stock——14,255,932USD—0USD80,214,008USD673,653USD14,126,525USD
    Begin Period Cash Flow——23,832,026USD53,825,166USD71,421,601USD12,232,418USD22,368,837USD17,321,862USD
    End Period Cash Flow——15,615,095USD23,832,026USD53,825,166USD71,421,601USD12,232,418USD22,368,837USD
    Other Cashflows From Investing Activities——-398,121USD-368,211USD-640,013USD-967,823USD-821,952USD-848,294USD
    Other Cashflows From Financing Activities——218,278USD-40,358USD805,199USD1,134,322USD2,504,026USD3,339,328USD
    Dividends Paid———-5,000,000USD————
    Sale Purchase Of Stock———-40,358USD-90,000USD1,509,322USD2,508,238USD3,487,316USD
    Cash And Cash Equivalents Changes———-29,730,216USD-17,596,435USD59,189,183USD-10,136,419USD5,046,975USD
    Exchange Rate Changes————-24,774USD130,357USD-35,199USD-58,930USD
    Unclassified Operating Cash Flow—————-2,709,449USD——
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ3 20242024-09-30 · USD
    Depreciation1,137,000USD773,000USD1,180,717USD
    Stock Based Compensation1,879,000USD1,391,000USD2,344,671USD
    Change To Account Receivables560,000USD257,000USD-628,510USD
    Change To Inventory-1,247,000USD-925,000USD429,004USD
    Change To Liabilities-167,000USD-360,000USD-3,165,684USD
    Change In Working Capital135,000USD869,000USD-2,859,525USD
    Operating Cash Flow-7,552,000USD-4,975,000USD-12,085,642USD
    Capital Expenditures-56,000USD-39,000USD—
    Unclassified Investing Cash Flow-68,000USD-140,000USD—
    Investing Cash Flow-124,000USD-179,000USD-545,237USD
    Financing Cash Flow6,831,000USD6,831,000USD9,163,844USD
    Effect Of Forex Changes On Cash139,000USD285,000USD21,226USD
    Change In Cash-706,000USD1,962,000USD-3,445,809USD
    End Cash Flow9,058,000USD11,700,000USD12,169,286USD
    Net Debt Issuance——10,000,000USD
    Unclassified Financing Cash Flow——-836,156USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinal

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30GeographyAll Other Countries6,892,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30GeographyGermany2,541,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30GeographyUnited States200,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31GeographyAll Other Countries6,133,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31GeographyGermany2,613,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31GeographyUnited States118,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30ProductCyto Sorb Sales8,586,274USDDisclosure
    Q3 2024Quarterly · 2024-09-30ProductGrant777,593USDDisclosure
    Q3 2024Quarterly · 2024-09-30ProductOther Sales26,521USDDisclosure
    Q2 2024Quarterly · 2024-06-30ProductCyto Sorb Sales8,830,391USD0001410578-24-001368
    Q2 2024Quarterly · 2024-06-30ProductGrant1,052,847USD0001410578-24-001368
    Q2 2024Quarterly · 2024-06-30ProductOther Sales11,398USD0001410578-24-001368
    Q1 2024Quarterly · 2024-03-31ProductCyto Sorb Sales8,964,790USD0001410578-24-000703
    Q1 2024Quarterly · 2024-03-31ProductGrant796,772USD0001410578-24-000703
    Q1 2024Quarterly · 2024-03-31ProductOther Sales24,730USD0001410578-24-000703
    Q4 2023Quarterly · 2023-12-31ProductCyto Sorb Sales7,334,085USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductGrant1,319,729USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductOther Sales14,401USDLegacy provider
    FY 2023Yearly · 2023-12-31ProductCyto Sorb Sales31,015,268USD0001410578-24-000201
    FY 2023Yearly · 2023-12-31ProductGrant5,264,426USD0001410578-24-000201
    FY 2023Yearly · 2023-12-31ProductOther Sales69,685USD0001410578-24-000201
    Q2 2023Quarterly · 2023-06-30ProductCyto Sorb Sales8,065,829USD0001410578-24-001368
    Q2 2023Quarterly · 2023-06-30ProductGrant1,348,409USD0001410578-24-001368
    Q2 2023Quarterly · 2023-06-30ProductOther Sales6,583USD0001410578-24-001368
    Q1 2023Quarterly · 2023-03-31ProductCyto Sorb Sales7,906,269USD0001410578-24-000703
    Q1 2023Quarterly · 2023-03-31ProductGrant1,539,457USD0001410578-24-000703
    Q1 2023Quarterly · 2023-03-31ProductOther Sales3,770USD0001410578-24-000703
    Q4 2022Quarterly · 2022-12-31ProductCyto Sorb Sales7,396,515USDLegacy provider
    Q4 2022Quarterly · 2022-12-31ProductGrant1,748,452USDLegacy provider
    Q4 2022Quarterly · 2022-12-31ProductOther Sales245,507USDLegacy provider
    FY 2022Yearly · 2022-12-31ProductCyto Sorb Sales28,572,709USD0001410578-24-000201
    FY 2022Yearly · 2022-12-31ProductGrant5,328,899USD0001410578-24-000201
    FY 2022Yearly · 2022-12-31ProductOther Sales787,201USD0001410578-24-000201
    Q3 2022Quarterly · 2022-09-30ProductCyto Sorb Sales6,271,228USD0001410578-23-002301
    Q3 2022Quarterly · 2022-09-30ProductGrant1,648,657USD0001410578-23-002301
    Q3 2022Quarterly · 2022-09-30ProductOther Sales191,468USD0001410578-23-002301
    Q1 2022Quarterly · 2022-03-31GeographyAll Other Countries4,695,556USD0001410578-23-000868
    Q1 2022Quarterly · 2022-03-31GeographyGermany3,783,526USD0001410578-23-000868
    Q1 2022Quarterly · 2022-03-31GeographyUnited States212,342USD0001410578-23-000868
    FY 2021Yearly · 2021-12-31ProductCyto Sorb Sales39,996,700USD0001410578-24-000201
    FY 2021Yearly · 2021-12-31ProductGrant3,056,960USD0001410578-24-000201
    FY 2021Yearly · 2021-12-31ProductOther Sales111,867USD0001410578-24-000201
    FY 2020Yearly · 2020-12-31ProductCyto Sorb Sales39,342,102USD0001410578-23-000234
    FY 2020Yearly · 2020-12-31ProductGrant1,552,099USD0001410578-23-000234
    FY 2020Yearly · 2020-12-31ProductOther Sales110,400USD0001410578-23-000234
    FY 2019Yearly · 2019-12-31ProductCyto Sorb Sales22,545,754USD0001410578-22-000331
    FY 2019Yearly · 2019-12-31ProductGrant2,183,619USD0001410578-22-000331
    FY 2019Yearly · 2019-12-31ProductOther Sales220,100USD0001410578-22-000331
    Q2 2019Quarterly · 2019-06-30GeographyAll Other Countries2,157,382USD0001144204-19-037883
    Q2 2019Quarterly · 2019-06-30GeographyGermany3,693,035USD0001144204-19-037883
    Q2 2019Quarterly · 2019-06-30GeographyUnited States0USD0001144204-19-037883
    Q1 2019Quarterly · 2019-03-31GeographyAll Other Countries1,411,603USD0001144204-19-024246
    Q1 2019Quarterly · 2019-03-31GeographyGermany3,098,176USD0001144204-19-024246
    Q1 2019Quarterly · 2019-03-31GeographyUnited States66,800USD0001144204-19-024246
    Q4 2018Quarterly · 2018-12-31GeographyAll Other Countries2,330,548USDLegacy provider
    Q4 2018Quarterly · 2018-12-31GeographyGermany3,105,036USDLegacy provider
    Q4 2018Quarterly · 2018-12-31GeographyUnited States35,200USDLegacy provider
    FY 2018Yearly · 2018-12-31ProductCyto Sorb Sales20,143,354USD0001104659-21-033790
    FY 2018Yearly · 2018-12-31ProductGrant2,251,525USD0001104659-21-033790
    FY 2018Yearly · 2018-12-31ProductOther Sales109,029USD0001104659-21-033790
    FY 2018Yearly · 2018-12-31GeographyAll Other Countries8,385,238USD0001144204-19-012774
    FY 2018Yearly · 2018-12-31GeographyGermany11,771,645USD0001144204-19-012774
    FY 2018Yearly · 2018-12-31GeographyUnited States95,500USD0001144204-19-012774
    Q3 2018Quarterly · 2018-09-30GeographyAll Other Countries2,335,826USD0001144204-18-057624
    Q3 2018Quarterly · 2018-09-30GeographyGermany2,766,922USD0001144204-18-057624
    Q3 2018Quarterly · 2018-09-30GeographyUnited States0USD0001144204-18-057624
    Q2 2018Quarterly · 2018-06-30GeographyAll Other Countries1,954,776USD0001144204-19-037883
    Q2 2018Quarterly · 2018-06-30GeographyGermany3,232,279USD0001144204-19-037883
    Q2 2018Quarterly · 2018-06-30GeographyUnited States58,500USD0001144204-19-037883
    FY 2017Yearly · 2017-12-31ProductCyto Sorb Sales13,254,953USD0001104659-20-029712
    FY 2017Yearly · 2017-12-31ProductGrant1,768,901USD0001104659-20-029712
    FY 2017Yearly · 2017-12-31ProductOther Sales126,900USD0001104659-20-029712
    FY 2017Yearly · 2017-12-31GeographyAll Other Countries5,348,102USD0001144204-19-012774
    FY 2017Yearly · 2017-12-31GeographyGermany7,906,851USD0001144204-19-012774
    FY 2017Yearly · 2017-12-31GeographyUnited States126,900USD0001144204-19-012774
    FY 2016Yearly · 2016-12-31GeographyAll Other Countries3,313,423USD0001144204-19-012774
    FY 2016Yearly · 2016-12-31GeographyGermany4,892,613USD0001144204-19-012774

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.